NEW YORK, March 23 – Vincent Kazmer said Friday he was resigning as chief financial officer of NetGenics to join Phase-1 Molecular Toxicology as CEO.
“Phase-1 is a good opportunity,” Kazmer said. His resignation is effective immediately and he will start work at Phase-1 Molecular Toxicology in April.
The company, which is based in Santa Fe, NM, uses gene expression technologies and bioinformatics to help improve lead optimization and diminish toxic effects early in a drug’s development.
Phase-1’s founder Spencer Farr will head the company’s R&D division.
"As the company continues to expand its operations and business into Europe and Japan, and seeks to capitalize on the significant opportunities at hand, it is crucial to have a seasoned business leader at the helm,” Farr said.
Prior to joining NetGenics Kazmer was CEO of Lark Technologies, a publicly traded molecular biology contract research organization.
NetGenics has not yet named a replacement for Kazmer. The Cleveland-based bioinformatics company recently laid off 29 of its 100 employees due to the downturn in the economic conditions, which forced the company to delay its IPO.